[go: up one dir, main page]

EP0572529A4 - Aptamere specifique de biomolecules et procede de production. - Google Patents

Aptamere specifique de biomolecules et procede de production.

Info

Publication number
EP0572529A4
EP0572529A4 EP9292907174A EP92907174A EP0572529A4 EP 0572529 A4 EP0572529 A4 EP 0572529A4 EP 9292907174 A EP9292907174 A EP 9292907174A EP 92907174 A EP92907174 A EP 92907174A EP 0572529 A4 EP0572529 A4 EP 0572529A4
Authority
EP
European Patent Office
Prior art keywords
biomolecules
production
specific aptamer
aptamer
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP9292907174A
Other languages
German (de)
English (en)
Other versions
EP0572529A1 (fr
Inventor
John J Toole
Linda C Griffin
Louis C Bock
John A Latham
Daryl Dean Muenchau
Steven Krawczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of EP0572529A1 publication Critical patent/EP0572529A1/fr
Publication of EP0572529A4 publication Critical patent/EP0572529A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
EP9292907174A 1991-02-21 1992-02-21 Aptamere specifique de biomolecules et procede de production. Withdrawn EP0572529A4 (fr)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US659103 1984-10-09
US659114 1984-10-09
US65998191A 1991-02-21 1991-02-21
US65911491A 1991-02-21 1991-02-21
US65884991A 1991-02-21 1991-02-21
US65911391A 1991-02-21 1991-02-21
US65879691A 1991-02-21 1991-02-21
US65910391A 1991-02-21 1991-02-21
US65998091A 1991-02-21 1991-02-21
US659113 1991-02-21
US659980 1991-02-21
US659981 1991-02-21
US658849 1991-02-21
US74487091A 1991-08-14 1991-08-14
US74521591A 1991-08-14 1991-08-14
US744870 1991-08-14
US745215 1991-08-14
US78792191A 1991-11-06 1991-11-06
US787921 1991-11-06
US658796 1996-06-05

Publications (2)

Publication Number Publication Date
EP0572529A1 EP0572529A1 (fr) 1993-12-08
EP0572529A4 true EP0572529A4 (fr) 1994-11-02

Family

ID=27581306

Family Applications (1)

Application Number Title Priority Date Filing Date
EP9292907174A Withdrawn EP0572529A4 (fr) 1991-02-21 1992-02-21 Aptamere specifique de biomolecules et procede de production.

Country Status (6)

Country Link
EP (1) EP0572529A4 (fr)
JP (1) JPH06508022A (fr)
AU (1) AU1435492A (fr)
CA (1) CA2104698A1 (fr)
IE (1) IE920562A1 (fr)
WO (1) WO1992014843A1 (fr)

Families Citing this family (292)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
EP1695978A1 (fr) 1990-06-11 2006-08-30 Gilead Sciences, Inc. Ligands constitués par des acides nucléiques
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5650275A (en) * 1990-06-11 1997-07-22 Nexstar Pharmacueticals Inc Target detection method using spectroscopically detectable nucleic acid ligands
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
AU2663292A (en) * 1991-09-10 1993-04-05 Jack D. Love Dna/rna target and signal amplification
EP0616612A4 (fr) 1991-12-12 1995-01-11 Gilead Sciences Inc Oligomeres stables a la nuclease et aptes aux liaisons et methodes d'utilisation.
ATE315101T1 (de) * 1992-09-29 2006-02-15 Gilead Sciences Inc Nukleinsäureliganden und ihre herstellungsmethoden
US6306598B1 (en) * 1992-11-13 2001-10-23 Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors
US5599917A (en) * 1994-03-17 1997-02-04 Pharmagenics, Inc. Inhibition of interferon-γ with oligonucleotides
EP0781332A2 (fr) * 1993-07-19 1997-07-02 Gen-Probe Incorporated Augmentation de l'inhibition oligonucleotidique de la production proteique, de la proliferation cellulaire et/ou de la multiplication d'agents pathogenes de maladie infectieuse
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
AU692212B2 (en) * 1993-12-17 1998-06-04 Roger S. Cubicciotti Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices
EP0754238A4 (fr) * 1994-04-05 1998-01-28 Pharmagenics Inc Determination et identification de composes actifs dans une bibliotheque de composes
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US6500669B1 (en) 1994-05-04 2002-12-31 Massachusetts Institute Of Technology Programmable genotoxic agents and uses therefor
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5998596A (en) * 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US5753787A (en) * 1995-04-10 1998-05-19 Yale University Nucleic acids encoding ancylostoma secreted protein
CA2219807C (fr) * 1995-05-03 2008-12-30 Nexstar Pharmaceuticals, Inc. Evolution systematique des ligands par enrichissement exponentiel: procede selex pour tissus
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
CA2641149A1 (fr) * 1995-05-03 1996-11-07 Bayer Schering Pharma Aktiengesellschaft Ligands a acide nucleique pour cibles tissulaires
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
CA2219119C (fr) * 1995-05-04 2012-10-23 Nexstar Pharmaceuticals, Inc. Complexes de ligand d'acide nucleique
EP0828849B1 (fr) 1995-06-02 2006-10-25 Gilead Sciences, Inc. Ligands oligonucleotidiques ayant une affinite elevee pour le pdgf
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
AU726844B2 (en) * 1995-06-07 2000-11-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
JPH11507529A (ja) * 1995-06-07 1999-07-06 ネクスター ファーマスーティカルズ，インコーポレイテッド サイトカインの高親和性核酸リガンド
CA2223275A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Ligands d'acide nucleique a haute affinite pour les lectines
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
WO1996040726A1 (fr) 1995-06-07 1996-12-19 Genta Incorporated Nouveaux lipides cationiques a base de carbamate
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
ATE468396T1 (de) 1996-02-01 2010-06-15 Gilead Sciences Inc Nukleinsäureliganden mit hoher affinität für das c1q protein des komplementsystems
JP2000507097A (ja) * 1996-03-12 2000-06-13 ベーリンガー マンハイム ゲーエムベーハー アルギニンに結合する単離されたｒｎａ分子およびその使用
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6838238B1 (en) * 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
AU730491B2 (en) 1997-05-16 2001-03-08 Exact Sciences Corporation Electrophoretic analysis of molecules using immobilized probes
AU8505898A (en) * 1997-07-22 1999-02-16 Genitrix, Llc Nucleic acid compositions and methods of introducing nucleic acids into cells
AU9210498A (en) * 1997-08-29 1999-03-16 Gilead Sciences, Inc. 5',5'-linked oligomers having anti-thrombin activity
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2220785A1 (fr) * 1997-12-02 1999-06-02 Noureddine Rouissi Technique selective d'identification rapide des proteines et des genes et usages pertinents
US20060057573A1 (en) 2002-02-15 2006-03-16 Somalogic, Inc Methods and reagents for detecting target binding by nucleic acid ligands
EP1049803A4 (fr) 1997-12-15 2002-08-21 Nexstar Pharmaceuticals Inc Detection homogene de molecules cibles par interaction ligand acide nucleique et ligand balise
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6180348B1 (en) * 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
WO2000009684A1 (fr) * 1998-08-14 2000-02-24 Japan Science And Technology Corporation Acide nucleique capable de se lier specifiquement a une proteine cible ras
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6780850B1 (en) 1999-06-22 2004-08-24 Triumf Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
CA2403708A1 (fr) 2000-03-22 2001-09-27 Quantum Dot Corporation Procedes d'utilisation de nanocristaux semi-conducteurs dans des tests d'acides nucleiques a base de billes
US20020098493A1 (en) * 2000-05-25 2002-07-25 Asher Nathan Drug-amino acids chimeric molecules
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6376190B1 (en) * 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP2325337A1 (fr) * 2000-09-26 2011-05-25 Duke University Aptamères d'ARN et leurs procédés d'identification
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
AU2002226876A1 (en) 2000-10-06 2002-04-15 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
JP4176466B2 (ja) 2000-10-16 2008-11-05 ギリード・サイエンシズ・インコーポレーテッド 前立腺特異的膜抗原に対する核酸リガンド
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
AU2002330968B2 (en) 2001-08-17 2007-03-22 Neose Technologies, Inc. Chemo-enzymatic synthesis of sialylated oligosaccharides
WO2003029492A1 (fr) * 2001-09-28 2003-04-10 Justin Gallivan Genes metaboliques et procedes et compositions associes
AU2002337312A1 (en) 2001-10-25 2003-05-06 Medical Research Council Molecules
WO2003051314A2 (fr) 2001-12-18 2003-06-26 Medallion Biomedical, Llc Composes antibiotiques
US20040023415A1 (en) 2002-03-05 2004-02-05 Konstantin Sokolov Biospecific contrast agents
EP1572927A4 (fr) 2002-04-08 2007-10-17 Pioneer Hi Bred Int Procedes d'amelioration de l'exsertion de la soie de mais lorsqu'elle est sujette a des agressions
EP1501929B1 (fr) * 2002-05-06 2013-03-27 Noxxon Pharma AG Acides nucleiques liant le cgrp
JP2005533794A (ja) * 2002-06-18 2005-11-10 アーケミックス コーポレイション アプタマー−毒素分子およびこれを使用する方法
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2492463A1 (fr) 2002-07-25 2004-02-05 Archemix Corporation Compositions therapeutiques aptameriques regulees
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
CA2749227A1 (fr) 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1597350B1 (fr) * 2003-02-27 2015-04-08 Yeda Research And Development Co., Ltd. Molecules d'acide nucleique, et compositions les contenant utiles dans le traitement et la detection de l'infection imputable au virus de la grippe
US8017755B2 (en) 2003-05-23 2011-09-13 President And Fellows Of Harvard College RNA-based transcriptional regulators
US7910523B2 (en) 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1493810A1 (fr) * 2003-06-30 2005-01-05 Gentium S.p.A. Aptamères pour la cathepsine G basés sur de l'ADN
US7803624B2 (en) 2003-09-30 2010-09-28 Cytyc Corporation Automated cytological sample classification
US7807351B2 (en) 2003-11-22 2010-10-05 Techno Medica Co., Ltd. Method of detecting target molecule by using aptamer
ES2674129T3 (es) 2004-02-12 2018-06-27 Archemix Llc Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
RU2006135119A (ru) * 2004-03-05 2008-04-10 Аркемикс Корп. (Us) Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1598428A1 (fr) * 2004-05-18 2005-11-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
WO2005112919A2 (fr) 2004-05-19 2005-12-01 Medarex, Inc. Bras de liaison chimiques et conjugues associes
WO2006033854A2 (fr) * 2004-09-07 2006-03-30 Archemix Corp. Aptameres au facteur de von willebrand et leur utilisation en tant qu'agents therapeutiques pour des maladies thrombotiques
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006029258A2 (fr) 2004-09-07 2006-03-16 Archemix Corp. Chimie medicale utilisant des aptameres
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
CA2601400A1 (fr) 2005-03-19 2006-09-28 Medical Research Council Ameliorations dans ou concernant le traitement et la prevention d'infections virales
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
US8637656B2 (en) 2005-07-05 2014-01-28 Ribomic Inc. Nucleic acid capable of binding to immunoglobulin G and use thereof
CN101258241A (zh) * 2005-07-05 2008-09-03 力博美科股份有限公司 与免疫球蛋白g结合的核酸及其利用方法
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
CA2630838A1 (fr) * 2005-11-23 2007-05-31 Georg Dewald Detection et traitement de l'oedeme de quincke associe a un medicament
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
CN101374965B (zh) * 2006-01-17 2013-08-14 私募蛋白质体公司 测试样品的多元化分析
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
AR061929A1 (es) 2006-07-18 2008-10-01 Noxxon Pharma Ag Acidos nucleicos de union al factor derivado de celulas estomales sdf-1
WO2008063933A2 (fr) 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Modulateurs de pak
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Ｎｅｃソフト株式会社 ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
AU2008275915B2 (en) 2007-07-17 2013-07-11 Somalogic Operating Co., Inc. Method for generating aptamers with improved off-rates
ES2614735T3 (es) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
DE102007063902B3 (de) * 2007-08-31 2017-11-23 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
DE102007041476B4 (de) * 2007-08-31 2017-03-30 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
EP2215238A2 (fr) 2007-11-20 2010-08-11 Pioneer Hi-Bred International Inc. Gènes de signalisation d'éthylène de maïs et modulation de ceux-ci pour améliorer la résistance des plantes au stress
WO2010070380A2 (fr) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Compositions doc1 et méthodes de traitement du cancer
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US20120003749A1 (en) * 2008-05-21 2012-01-05 Nec Soft, Ltd. Nucleic acid molecule capable of binding to 2,4,6-trinitrophenyl skeleton, method for detecting compound having 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, and use of the nucleic acid molecule
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
UA104297C2 (en) 2008-08-14 2014-01-27 Сефалон Острейлиа Пти Лтд Anti-il-12/il-23 antibody
RS55218B1 (sr) 2008-10-31 2017-02-28 Janssen Biotech Inc Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe
RU2401306C2 (ru) * 2008-12-17 2010-10-10 Научно-исследовательский институт Физико-химической биологии имени А.Н. Белозерского Московского Государственного Университета имени М.В. Ломоносова Аптамерный олигонуклеотид - прямой ингибитор тромбина
MX2011008566A (es) 2009-02-12 2011-11-29 Janssen Biotech Inc Composiciones supercontigo basadas en el dominio de fibronectina tipo iii, metodos y usos.
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
KR101893011B1 (ko) 2009-04-03 2018-08-30 김성천 압타머 표적화 복합체의 제조방법
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20100291706A1 (en) 2009-05-15 2010-11-18 Millipore Corporation Dye conjugates and methods of use
WO2011017492A2 (fr) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Nouveaux gènes eto1 et leur utilisation pour une teneur en éthylène réduite et une tolérance au stress améliorée chez les plantes
WO2011061351A1 (fr) * 2009-11-23 2011-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Aptamères dirigés contre la protéine de matrice 1 de virus de la grippe de type a et leurs utilisations
EP2533810B1 (fr) 2010-02-10 2016-10-12 ImmunoGen, Inc. Anticorps anti-cd20 et utilisations de ceux-ci
WO2011109642A1 (fr) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamères pouvant se lier à 4-1bb et utilisation associée dans le traitement de maladies et de troubles
WO2011130195A1 (fr) 2010-04-12 2011-10-20 Somalogic, Inc. Aptamères de β-ngf et leur utilisation dans le traitement de maladies et de troubles à médiation par β-ngf
WO2011132672A1 (fr) * 2010-04-19 2011-10-27 独立行政法人理化学研究所 Procédé de stabilisation des acides nucléiques fonctionnels
US20110306653A1 (en) 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
JP2012196197A (ja) * 2011-03-04 2012-10-18 Kanagawa Acad Of Sci & Technol 標的細胞表面の標的分子に特異的に結合する核酸の選択法
EP2497828A1 (fr) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Utilisation d'aptamères pour la thérapie et/ou le diagnostic des maladies auto-immunes
US20140194320A1 (en) 2011-08-12 2014-07-10 Tagcyx Bitoecnologies Method for preparing nucleic acid aptamer
AR088515A1 (es) 2011-10-25 2014-06-18 Pioneer Hi Bred Int Metodos para alterar la composicion de la pared celular vegetal para obtener produccion de biocombustible y digestibilidad de silaje mejoradas
CN103958683A (zh) * 2011-12-28 2014-07-30 希森美康株式会社 与肾上腺皮质刺激激素结合的分子及其应用
WO2013142255A2 (fr) 2012-03-22 2013-09-26 University Of Miami Agents de liaison multi-spécifiques
US20150337308A1 (en) * 2012-04-11 2015-11-26 Chu De Bordeaux Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
US20160024516A1 (en) 2013-03-15 2016-01-28 Pioneer Hi-Bred International, Inc. Modulation of ACC Deaminase Expression
EP3008094B1 (fr) 2013-06-14 2018-12-26 Pacific Biosciences Of California, Inc. Étiquettes de bis-biotinylation
US9765375B2 (en) 2013-06-28 2017-09-19 General Electric Company Methods for developing binding-elements and uses thereof
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
MX373950B (es) 2014-05-29 2020-07-13 Quark Pharmaceuticals Inc USO DE UN INHIBIDOR TEMPORAL DE UN GEN p53 PARA LA PROFILAXIS DE LESIÓN POR ISQUEMIA-REPERFUSIÓN.
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
AU2017241776B2 (en) 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
WO2017175058A1 (fr) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification
BR112019000693A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics, Inc. composições de muc1- car e métodos para uso
CN109890841A (zh) 2016-07-15 2019-06-14 波赛达治疗公司 嵌合抗原受体及使用方法
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
US10947545B2 (en) * 2016-11-23 2021-03-16 Berlin Cures GmbH Aptamers for use in inhibition and/or suppression of TLR9 activation
CA3052095A1 (fr) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et methodes pour le traitement du rhumatisme psoriasique actif
IL319561A (en) 2017-02-07 2025-05-01 Janssen Biotech Inc Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
CN117959418A (zh) 2017-03-13 2024-05-03 波赛达治疗公司 用于选择性消除和替换造血干细胞的组合物和方法
KR101993427B1 (ko) * 2017-04-26 2019-10-01 주식회사 압타머사이언스 백혈구에 선택적으로 결합하는 압타머 및 이의 용도
CN111727256A (zh) 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3728305A1 (fr) 2017-12-20 2020-10-28 Poseida Therapeutics, Inc. Compositions de vcar et méthodes d'utilisation
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
WO2019215701A1 (fr) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Méthodes de traitement de la dépression à l'aide d'anticorps il-23
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
CA3124103A1 (fr) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Compositions de nanotransposons et procedes d'utilisation
CN113365661A (zh) 2019-01-31 2021-09-07 新加坡科技研究局 用于治疗或预防癌症的cnx/erp57抑制剂
MA55282A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
JP7662529B2 (ja) 2019-03-14 2025-04-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
EP3938391A1 (fr) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Procédés de production de compositions d'anticorps anti-tnf
CA3134079A1 (fr) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Methode de traitement du psoriasis chez des sujets pediatriques avec un anticorps anti-il12/il23
CN110172498B (zh) * 2019-04-28 2022-09-20 广东省微生物研究所（广东省微生物分析检测中心） 一种快速高效分析转录因子及其靶dna结合序列相互作用的方法
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
AU2020288404A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
WO2020245676A1 (fr) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
JP2022536088A (ja) 2019-06-04 2022-08-12 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
KR20220057596A (ko) 2019-09-05 2022-05-09 포세이다 테라퓨틱스, 인크. 동종이계 세포 조성물 및 사용 방법
CA3162246A1 (fr) 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Compositions anti-muc1 et methodes d'utilisation
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
BR112022020650A2 (pt) 2020-04-14 2023-01-31 Poseida Therapeutics Inc Composições e métodos para uso no tratamento de câncer
IL297906A (en) 2020-05-05 2023-01-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
WO2022087148A1 (fr) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions et procédés d'administration d'acides nucléiques
CN112778432B (zh) * 2021-02-01 2022-04-22 西藏天虹科技股份有限责任公司 波棱瓜子多糖提取方法
EP4367136A1 (fr) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
WO2023060088A1 (fr) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Compositions de transposons et leurs procédés d'utilisation
WO2023073615A1 (fr) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
WO2023141576A1 (fr) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions et procédés d'administration d'acides nucléiques
EP4499689A1 (fr) 2022-03-30 2025-02-05 Janssen Biotech, Inc. Méthode de traitement du psoriasis léger à modéré avec un anticorps spécifique d'il-23
KR20250011938A (ko) 2022-05-18 2025-01-22 얀센 바이오테크 인코포레이티드 Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
CN115537419B (zh) * 2022-09-27 2025-02-11 福州大学 一种尿苷二磷酸的核酸适体及其筛选方法和应用
CN120569403A (zh) 2022-11-22 2025-08-29 詹森生物科技公司 用抗il23特异性抗体治疗溃疡性结肠炎的方法
WO2025160432A1 (fr) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Méthodes et compositions pour améliorer la persistance in vivo et l'efficacité d'une thérapie cellulaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019813A1 (fr) * 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Ligands d'acide nucleique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0689014B2 (ja) * 1986-01-21 1994-11-09 興和株式会社 トロンビン結合性物質およびその製法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019813A1 (fr) * 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Ligands d'acide nucleique

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOCK L C ET AL: "SELECTION OF SINGLE-STRANDED DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN", NATURE, vol. 355, no. 6360, 6 February 1992 (1992-02-06), pages 564 - 566, XP000453533 *
See also references of WO9214843A1 *
THIESEN H J ET AL: "TARGET DETECTION ASSAY (TDA): A VERSATILE PROCEDURE TO DETERMINE DNA BINDING SITES AS DEMONSTRATED ON SP1 PROTEIN", NUCLEIC ACIDS RESEARCH, vol. 18, no. 11, 11 June 1990 (1990-06-11), pages 3203 - 3209, XP000132496 *

Also Published As

Publication number Publication date
EP0572529A1 (fr) 1993-12-08
WO1992014843A1 (fr) 1992-09-03
CA2104698A1 (fr) 1992-08-22
AU1435492A (en) 1992-09-15
IE920562A1 (en) 1992-08-26
JPH06508022A (ja) 1994-09-14

Similar Documents

Publication Publication Date Title
EP0572529A4 (fr) Aptamere specifique de biomolecules et procede de production.
DE3880869D1 (de) Verstaerkter glasgegenstand und verfahren zu dessen herstellung.
DE69407295D1 (de) Anorganisches, poröses material und verfahren zu dessen herstellung
DE3879613D1 (de) Schnellrueckstellbares ptfe und verfahren zu dessen herstellung.
DE3879320D1 (de) Copolyester und verfahren zu dessen herstellung.
DE69406098D1 (de) Isolationssystem für fahrzeuge und verfahren zu dessen erzeugung und verwendung
DE69022920D1 (de) Greifmittel für Artikel und Verfahren zu dessen Herstellung.
DE59002338D1 (de) Biegeelastisches kupplungselement und verfahren zu dessen herstellung.
DE69006318D1 (de) Glasiertes Metallrohr und Verfahren zu dessen Herstellung.
DE69112884D1 (de) Ionensensor und Verfahren zu dessen Herstellung und Verwendung.
DE59502879D1 (de) Ausweiskarte und verfahren zu deren herstellung
DE69516857D1 (de) Klebestreifen für die buchbinderei und verfahren zu dessen herstellung
DE3882319D1 (de) Lederartiges schichtprodukt und verfahren zu dessen herstellung.
DE59107046D1 (de) Schichtsystem für gassensoren und verfahren zu dessen herstellung.
DE69837849D1 (de) Kohlekommutator und verfahren zu dessen herstellung
DE3583912D1 (de) Feuchtigkeitsfuehler und verfahren zu dessen herstellung.
DE69503332D1 (de) Gleitstück und verfahren zu dessen herstellung
DE3671530D1 (de) Ionensensor und verfahren zu dessen herstellung.
DE69009532D1 (de) Umwickelelement für ringförmigen Artikel und Verfahren zu dessen Herstellung.
DE69021221D1 (de) Kohlebindemittel und Verfahren zu dessen Herstellung.
DE69003403D1 (de) Phosphatierlösung für Komplexstrukturen und Verfahren zu ihrer Verwendung.
DE69108973D1 (de) Verfahren und Vorrichtung zur Produktion gasförmigen Stickstoffs und System zu dessen Bereitstellung.
DE68917918D1 (de) Kryogenes verfahren für metallabzug.
DE69738163D1 (de) Bauteil für ein ordnungsregal und verfahren zu dessen verwendung
DE68923277D1 (de) Vliesstoff aus metallfasern und verfahren zu dessen herstellung.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940916

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19970423

17Q First examination report despatched

Effective date: 19980603

18D Application deemed to be withdrawn

Effective date: 19981215